Search

Your search keyword '"Ozkaynak M"' showing total 334 results
Start Over Author "Ozkaynak M"
334 results on '"Ozkaynak M"'

1. Measurement of the double-differential cross section of muon-neutrino charged-current interactions with low hadronic energy in the NOvA Near Detector

Author

Acero, M. A., Acharya, B., Adamson, P., Aliaga, L., Anfimov, N., Antoshkin, A., Arrieta-Diaz, E., Asquith, L., Aurisano, A., Back, A., Balashov, N., Baldi, P., Bambah, B. A., Bannister, E., Barros, A., Bashar, S., Bat, A., Bays, K., Bernstein, R., Bezerra, T. J. C., Bhatnagar, V., Bhattarai, D., Bhuyan, B., Bian, J., Booth, A. C., Bowles, R., Brahma, B., Bromberg, C., Buchanan, N., Butkevich, A., Calvez, S., Carroll, T. J., Catano-Mur, E., Cesar, J. P., Chatla, A., Chirco, R., Choudhary, B. C., Christensen, A., Cicala, M. F., Coan, T. E., Cooleybeck, A., Cortes-Parra, C., Coveyou, D., Cremonesi, L., Davies, G. S., Derwent, P. F., Ding, P., Djurcic, Z., Dobbs, K., Dolce, M., Doyle, D., Tonguino, D. Dueñas, Dukes, E. C., Dye, A., Ehrlich, R., Ewart, E., Filip, P., Frank, M. J., Gallagher, H. R., Gao, F., Giri, A., Gomes, R. A., Goodman, M. C., Groh, M., Group, R., Habig, A., Hakl, F., Hartnell, J., Hatcher, R., He, M., Heller, K., Hewes, V, Himmel, A., Horoho, T., Ivaneev, Y., Ivanova, A., Jargowsky, B., Jarosz, J., Johnson, C., Judah, M., Kakorin, I., Kaplan, D. M., Kalitkina, A., Kirezli-Ozdemir, B., Kleykamp, J., Klimov, O., Koerner, L. W., Kolupaeva, L., Kralik, R., Kumar, A., Kus, V., Lackey, T., Lang, K., Lesmeister, J., Lister, A., Liu, J., Lock, J. A., Lokajicek, M., MacMahon, M., Magill, S., Mann, W. A., Manoharan, M. T., Plata, M. Manrique, Marshak, M. L., Martinez-Casales, M., Matveev, V., Mehta, B., Messier, M. D., Meyer, H., Miao, T., Miller, W. H., Mishra, S., Mishra, S. R., Mislivec, A., Mohanta, R., Moren, A., Morozova, A., Mu, W., Mualem, L., Muether, M., Mulder, K., Myers, D., Naples, D., Nath, A., Nelleri, S., Nelson, J. K., Nichol, R., Niner, E., Norman, A., Norrick, A., Nosek, T., Oh, H., Olshevskiy, A., Olson, T., Ozkaynak, M., Pal, A., Paley, J., Panda, L., Patterson, R. B., Pawloski, G., Petti, R., Porter, J. C. C., Prais, L. R., Rabelhofer, M., Rafique, A., Raj, V., Rajaoalisoa, M., Ramson, B., Rebel, B., Roy, P., Samoylov, O., Sanchez, M. C., Falero, S. Sanchez, Shanahan, P., Sharma, P., Sheshukov, A., Shivam, Shmakov, A., Shorrock, W., Shukla, S., Singha, D. K., Singh, I., Singh, P., Singh, V., Smith, E., Smolik, J., Snopok, P., Solomey, N., Sousa, A., Soustruznik, K., Strait, M., Suter, L., Sutton, A., Sutton, K., Swain, S., Sweeney, C., Sztuc, A., Talukdar, N., Oregui, B. Tapia, Tas, P., Thakore, T., Thomas, J., Tiras, E., Titus, M., Torun, Y., Tran, D., Trokan-Tenorio, J., Urheim, J., Vahle, P., Vallari, Z., Villamil, J. D., Vockerodt, K. J., Wallbank, M., Weber, C., Wetstein, M., Whittington, D., Wickremasinghe, D. A., Wieber, T., Wolcott, J., Wrobel, M., Wu, S., Wu, W., Xiao, Y., Yaeggy, B., Yahaya, A., Yankelevich, A., Yonehara, K., Yu, Y., Zadorozhnyy, S., Zalesak, J., and Zwaska, R.

Subjects
High Energy Physics - Experiment
Abstract

The NOvA collaboration reports cross-section measurements for $\nu_{\mu}$ charged-current interactions with low hadronic energy (maximum kinetic energy of 250 MeV for protons and 175 MeV for pions) in the NOvA Near Detector. The results are presented as a double-differential cross section as a function of the direct observables of the final-state muon kinematics. Results are also presented as a single-differential cross section as a function of the derived square of the four-momentum transfer, $Q^{2}$, and as a function of the derived neutrino energy. The data correspond to an accumulated 8.09$\times10^{20}$ protons-on-target (POT) in the neutrino mode of the NuMI beam, with a narrow band of neutrino energies peaked at 1.8 GeV. The analysis provides a sample of neutrino-nucleus interactions with an enhanced fraction of quasi-elastic and two-particle-two-hole (2p2h) interactions. This enhancement allows quantitative comparisons with various nuclear models. We find strong disagreement between data and theory-based models in various regions of the muon kinematic phase space, especially in the forward muon direction., Comment: 20 pages, 12 figures. The second version includes an additional citation and adds four previously missing authors

Published
2024

2. Measurement of d2sigma/d|q|dEavail in charged current neutrino-nucleus interactions at <Ev> = 1.86 GeV using the NOvA Near Detector

Author

Acero, M. A., Acharya, B., Adamson, P., Aliaga, L., Anfimov, N., Antoshkin, A., Arrieta-Diaz, E., Asquith, L., Aurisano, A., Back, A., Balashov, N., Baldi, P., Bambah, B. A., Bannister, E., Barros, A., Bashar, S., Bat, A., Bays, K., Bernstein, R., Bezerra, T. J. C., Bhatnagar, V., Bhattarai, D., Bhuyan, B., Bian, J., Booth, A. C., Bowles, R., Brahma, B., Bromberg, C., Buchanan, N., Butkevich, A., Calvez, S., Carroll, T. J., Catano-Mur, E., Cesar, J. P., Chatla, A., Chirco, R., Choudhary, B. C., Christensen, A., Cicala, M. F., Coan, T. E., Cooleybeck, A., Cortes-Parra, C., Coveyou, D., Cremonesi, L., Davies, G. S., Derwent, P. F., Ding, P., Djurcic, Z., Dobbs, K., Dolce, M., Doyle, D., Tonguino, D. Duenas, Dukes, E. C., Dye, A., Ehrlich, R., Ewart, E., Filip, P., Frank, M. J., Gallagher, H. R., Gao, F., Giri, A., Gomes, R. A., Goodman, M. C., Groh, M., Group, R., Habig, A., Hakl, F., Hartnell, J., Hatcher, R., He, M., Heller, K., Hewes, V, Himmel, A., Horoho, T., Ivaneev, Y., Ivanova, A., Jargowsky, B., Jarosz, J., Johnson, C., Judah, M., Kakorin, I., Kaplan, D. M., Kalitkina, A., Kirezli-Ozdemir, B., Kleykamp, J., Klimov, O., Koerner, L. W., Kolupaeva, L., Kralik, R., Kumar, A., Kuruppu, C. D., Kus, V., Lackey, T., Lang, K., Lesmeister, J., Lister, A., Liu, J., Lock, J. A., Lokajicek, M., MacMahon, M., Magill, S., Mann, W. A., Manoharan, M. T., Plata, M. Manrique, Marshak, M. L., Martinez-Casales, M., Matveev, V., Mehta, B., Messier, M. D., Meyer, H., Miao, T., Miller, W. H., Mishra, S., Mishra, S. R., Mohanta, R., Moren, A., Morozova, A., Mu, W., Mualem, L., Muether, M., Mulder, K., Myers, D., Naples, D., Nath, A., Nelleri, S., Nelson, J. K., Nichol, R., Niner, E., Norman, A., Norrick, A., Nosek, T., Oh, H., Olshevskiy, A., Olson, T., Ozkaynak, M., Pal, A., Paley, J., Panda, L., Patterson, R. B., Pawloski, G., Petti, R., Plunkett, R. K., Prais, L. R., Rabelhofer, M., Rafique, A., Raj, V., Rajaoalisoa, M., Ramson, B., Rebel, B., Roy, P., Samoylov, O., Sanchez, M. C., Falero, S. Sanchez, Shanahan, P., Sharma, P., Sheshukov, A., Shivam, Shmakov, A., Shorrock, W., Shukla, S., Singha, D. K., Singh, I., Singh, P., Singh, V., Smith, E., Smolik, J., Snopok, P., Solomey, N., Sousa, A., Soustruznik, K., Strait, M., Suter, L., Sutton, A., Sutton, K., Swain, S., Sweeney, C., Sztuc, A., Oregui, B. Tapia, Tas, P., Thakore, T., Thomas, J., Tiras, E., Torun, Y., Tran, D., Trokan-Tenorio, J., Urheim, J., Vahle, P., Vallari, Z., Villamil, J. D., Vockerodt, K. J., Wallbank, M., Wetstein, M., Whittington, D., Wickremasinghe, D. A., Wieber, T., Wolcott, J., Wrobel, M., Wu, S., Wu, W., Xiao, Y., Yaeggy, B., Yahaya, A., Yankelevich, A., Yonehara, K., Yu, Y., Zadorozhnyy, S., Zalesak, J., and Zwaska, R.

Subjects
High Energy Physics - Experiment
Abstract

Double- and single-differential cross sections for inclusive charged-current neutrino-nucleus scattering are reported for the kinematic domain 0 to 2 GeV/c in three-momentum transfer and 0 to 2 GeV in available energy, at a mean muon-neutrino energy of 1.86 GeV. The measurements are based on an estimated 995,760 muon-neutrino CC interactions in the scintillator medium of the NOvA Near Detector. The subdomain populated by 2-particle-2-hole reactions is identified by the cross-section excess relative to predictions for neutrino-nucleus scattering that are constrained by a data control sample. Models for 2-particle-2- hole processes are rated by chi-square comparisons of the predicted-versus-measured muon-neutrino CC inclusive cross section over the full phase space and in the restricted subdomain. Shortfalls are observed in neutrino generator predictions obtained using the theory-based Val`encia and SuSAv2 2p2h models., Comment: 20 pages, 14 figures

Published
2024

3. Search for CP-violating Neutrino Non-Standard Interactions with the NOvA Experiment

Author

NOvA Collaboration, Acero, M. A., Acharya, B., Adamson, P., Aliaga, L., Anfimov, N., Antoshkin, A., Arrieta-Diaz, E., Asquith, L., Aurisano, A., Back, A., Balashov, N., Baldi, P., Bambah, B. A., Bat, A., Bays, K., Bernstein, R., Bezerra, T. J. C., Bhatnagar, V., Bhattarai, D., Bhuyan, B., Bian, J., Booth, A. C., Bowles, R., Brahma, B., Bromberg, C., Buchanan, N., Butkevich, A., Calvez, S., Carroll, T. J., Catano-Mur, E., Cesar, J. P., Chatla, A., Chaudhary, S., Chirco, R., Choudhary, B. C., Christensen, A., Cicala, M. F., Coan, T. E., Cooleybeck, A., Cortes-Parra, C., Coveyou, D., Cremonesi, L., Davies, G. S., Derwent, P. F., Djurcic, Z., Dolce, M., Doyle, D., Tonguino, D. Dueñas, Dukes, E. C., Dye, A., Ehrlich, R., Ewart, E., Filip, P., Franc, J., Frank, M. J., Gallagher, H. R., Gao, F., Giri, A., Gomes, R. A., Goodman, M. C., Groh, M., Group, R., Habig, A., Hakl, F., Hartnell, J., Hatcher, R., He, M., Heller, K., Hewes, V, Himmel, A., Ivaneev, Y., Ivanova, A., Jargowsky, B., Jarosz, J., Johnson, C., Judah, M., Kakorin, I., Kaplan, D. M., Kalitkina, A., Kleykamp, J., Klimov, O., Koerner, L. W., Kolupaeva, L., Kralik, R., Kumar, A., Kuruppu, C. D., Kus, V., Lackey, T., Lang, K., Lesmeister, J., Lister, A., Liu, J., Lock, J. A., Lokajicek, M., MacMahon, M., Magill, S., Mann, W. A., Manoharan, M. T., Plata, M. Manrique, Marshak, M. L., Martinez-Casales, M., Matveev, V., Mehta, B., Messier, M. D., Meyer, H., Miao, T., Mikola, V., Miller, W. H., Mishra, S., Mishra, S. R., Mislivec, A., Mohanta, R., Moren, A., Morozova, A., Mu, W., Mualem, L., Muether, M., Mulder, K., Myers, D., Naples, D., Nath, A., Nelleri, S., Nelson, J. K., Nichol, R., Niner, E., Norman, A., Norrick, A., Nosek, T., Oh, H., Olshevskiy, A., Olson, T., Ozkaynak, M., Pal, A., Paley, J., Panda, L., Patterson, R. B., Pawloski, G., Petrova, O., Petti, R., Prais, L. R., Rafique, A., Raj, V., Rajaoalisoa, M., Ramson, B., Ravelhofer, M., Rebel, B., Roy, P., Samoylov, O., Sanchez, M. C., Falero, S. Sánchez, Shanahan, P., Sharma, P., Shmakov, A., Sheshukov, A., Shukla, S., Singha, D. K., Shorrock, W., Singh, I., Singh, P., Singh, V., Smith, E., Smolik, J., Snopok, P., Solomey, N., Sousa, A., Soustruznik, K., Strait, M., Suter, L., Sutton, A., Sutton, K., Swain, S., Sweeney, C., Sztuc, A., Oregui, B. Tapia, Tas, P., Thakore, T., Thomas, J., Tiras, E., Torun, Y., Tripathi, J., Trokan-Tenorio, J., Urheim, J., Vahle, P., Vallari, Z., Vasel, J., Villamil, J. D., Vockerodt, K. J., Vrba, T., Wallbank, M., Wetstein, M., Whittington, D., Wickremasinghe, D. A., Wieber, T., Wolcott, J., Wrobel, M., Wu, S., Wu, W., Xiao, Y., Yaeggy, B., Yahaya, A., Yankelevich, A., Yonehara, K., Yu, Y., Zadorozhnyy, S., Zalesak, J., and Zwaska, R.

Subjects
High Energy Physics - Experiment, High Energy Physics - Phenomenology
Abstract

This Letter reports a search for charge-parity (CP) symmetry violating non-standard interactions (NSI) of neutrinos with matter using the NOvA Experiment, and examines their effects on the determination of the standard oscillation parameters. Data from $\nu_{\mu}(\bar{\nu}_{\mu})\rightarrow\nu_{\mu}(\bar{\nu}_{\mu})$ and $\nu_{\mu}(\bar{\nu}_{\mu})\rightarrow\nu_{e}(\bar{\nu}_{e})$ oscillation channels are used to measure the effect of the NSI parameters $\varepsilon_{e\mu}$ and $\varepsilon_{e\tau}$. With 90% C.L. the magnitudes of the NSI couplings are constrained to be $|\varepsilon_{e\mu}| \, \lesssim 0.3$ and $|\varepsilon_{e\tau}| \, \lesssim 0.4$. A degeneracy at $|\varepsilon_{e\tau}| \, \approx 1.8$ is reported, and we observe that the presence of NSI limits sensitivity to the standard CP phase $\delta_{\tiny\text{CP}}$.

Published
2024

6. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Long-Term Follow-up of Immunotherapy for Neuroblastoma

Author

Yu, Alice L, Gilman, Andrew L, Ozkaynak, M Fevzi, Naranjo, Arlene, Diccianni, Mitchell B, Gan, Jacek, Hank, Jacquelyn A, Batova, Ayse, London, Wendy B, Tenney, Sheena C, Smith, Malcolm, Shulkin, Barry L, Parisi, Marguerite, Matthay, Katherine K, Cohn, Susan L, Maris, John M, Bagatell, Rochelle, Park, Julie R, and Sondel, Paul M

Subjects
Immunization, Rare Diseases, Cancer, Neurosciences, Neuroblastoma, Clinical Trials and Supportive Activities, Pediatric, Vaccine Related, Pediatric Cancer, Prevention, Clinical Research, Adolescent, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Follow-Up Studies, Humans, Infant, Interleukin-2, Isotretinoin, Male, Progression-Free Survival, Recombinant Proteins, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreviously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolidation therapy. These results served as the basis for FDA approval of dinutuximab. We now present long-term follow-up results and evaluation of predictive biomarkers.Patients and methodsPatients recieved six cycles of isotretinoin with or without five cycles of immunotherapy which consists of dinutuximab with GM-CSF alternating with IL2. Accrual was discontinued early due to meeting the protocol-defined stopping rule for efficacy, as assessed by 2-year event-free survival (EFS). Plasma levels of dinutuximab, soluble IL2 receptor (sIL2R), and human anti-chimeric antibody (HACA) were assessed by ELISA. Fcγ receptor 2A and 3A genotypes were determined by PCR and direct sequencing.ResultsFor 226 eligible randomized patients, 5-year EFS was 56.6 ± 4.7% for patients randomized to immunotherapy (n = 114) versus 46.1 ± 5.1% for those randomized to isotretinoin only (n = 112; P = 0.042). Five-year overall survival (OS) was 73.2 ± 4.2% versus 56.6 ± 5.1% for immunotherapy and isotretinoin only patients, respectively (P = 0.045). Thirteen of 122 patients receiving dinutuximab developed HACA. Plasma levels of dinutuximab, HACA, and sIL2R did not correlate with EFS/OS, or clinically significant toxicity. Fcγ receptor 2A and 3A genotypes did not correlate with EFS/OS.ConclusionsImmunotherapy with dinutuximab improved outcome for patients with high-risk neuroblastoma. Early stoppage for efficacy resulted in a smaller sample size than originally planned, yet clinically significant long-term differences in survival were observed.

Published
2021

7. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.

Author

Hochberg, Jessica, Zahler, Stacey, Geyer, Mark B, Chen, Nan, Krajewski, Jennifer, Harrison, Lauren, Militano, Olga, Ozkaynak, M Fevzi, Cheerva, Alexandra C, Talano, Julie, Moore, Theodore B, Gillio, Alfred P, Walters, Mark C, Baxter-Lowe, Lee Ann, Hamby, Carl, and Cairo, Mitchell S

Subjects
Humans, Leukemia, Acute Disease, Cytarabine, Antineoplastic Combined Chemotherapy Protocols, Myeloablative Agonists, Treatment Outcome, Transplantation Conditioning, Whole-Body Irradiation, Hematopoietic Stem Cell Transplantation, Transplantation, Homologous, Adolescent, Child, Child, Preschool, Infant, Female, Male, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Clofarabine, Immunology, Clinical Sciences, Oncology and Carcinogenesis
Abstract

Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine (doses 40 - 52 mg/m2), cytarabine 1000 mg/m2, and 1200 cGy TBI followed by alloSCT in children, adolescents, and young adults with poor-risk leukemia. Thirty-seven patients; Age 12 years (1-22 years); ALL/AML: 34:3 (18 IF, 10 CR3, 13 refractory relapse); 15 related, 22 unrelated donors. Probabilities of neutrophil, platelet engraftment, acute GvHD, and chronic GvHD were 94%, 84%, 49%, and 30%, respectively. Probability of day 100 TRM was 8.1%. 2-year EFS (event free survival) and OS (overall survival) were 38.6% (CI95: 23-54%), and 41.3% (CI95: 25-57%). Multivariate analysis demonstrated overt disease at time of transplant (relative risk (RR) 3.65, CI95: 1.35-9.89, P = 0.011) and umbilical cord blood source (RR 2.17, CI95: 1.33-4.15, P = 0.019) to be predictors of worse EFS/OS. This novel myeloablative conditioning regimen followed by alloSCT is safe and well tolerated in CAYA with very poor-risk ALL or AML. Further investigation in CAYA with better risk ALL and AML undergoing alloSCT is warranted.

Published
2019

8. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Author

Erbe, Amy K, Wang, Wei, Carmichael, Lakeesha, Kim, KyungMann, Mendonça, Eneida A, Song, Yiqiang, Hess, Dustin, Reville, Patrick K, London, Wendy B, Naranjo, Arlene, Hank, Jacquelyn A, Diccianni, Mitchell B, Reisfeld, Ralph A, Gillies, Stephen D, Matthay, Katherine K, Cohn, Susan L, Hogarty, Michael D, Maris, John M, Park, Julie R, Ozkaynak, M Fevzi, Gilman, Andrew L, Yu, Alice L, and Sondel, Paul M

Subjects
Neurosciences, Immunization, Pediatric, Cancer, Rare Diseases, Pediatric Research Initiative, Clinical Trials and Supportive Activities, Neuroblastoma, Genetics, Clinical Research, Pediatric Cancer, Vaccine Related, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Cell Line, Tumor, Clinical Trials, Phase III as Topic, Female, Genotype, Humans, Immunotherapy, Ligands, Male, Receptors, KIR, Receptors, KIR2DL1, Receptors, KIR3DL1, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL2, and isotretinoin compared with treatment with isotretinoin alone. Dinutuximab, a chimeric anti-GD2 monoclonal antibody, acts in part via natural killer (NK) cells. Killer immunoglobulin-like receptors (KIR) on NK cells and their interactions with KIR-ligands can influence NK cell function. We investigated whether KIR/KIR-ligand genotypes were associated with EFS or OS in this trial.Experimental Design: We genotyped patients from COG study ANBL0032 and evaluated the effect of KIR/KIR-ligand genotypes on clinical outcomes. Cox regression models and log-rank tests were used to evaluate associations of EFS and OS with KIR/KIR-ligand genotypes.Results: In this trial, patients with the "all KIR-ligands present" genotype as well as patients with inhibitory KIR2DL2 with its ligand (HLA-C1) together with inhibitory KIR3DL1 with its ligand (HLA-Bw4) were associated with improved outcome if they received immunotherapy. In contrast, for patients with the complementary KIR/KIR-ligand genotypes, clinical outcome was not significantly different for patients who received immunotherapy versus those receiving isotretinoin alone.Conclusions: These data show that administration of immunotherapy is associated with improved outcome for neuroblastoma patients with certain KIR/KIR-ligand genotypes, although this was not seen for patients with other KIR/KIR-ligand genotypes. Further investigation of KIR/KIR-ligand genotypes may clarify their role in cancer immunotherapy and may enable KIR/KIR-ligand genotyping to be used prospectively for identifying patients likely to benefit from certain cancer immunotherapy regimens. Clin Cancer Res; 24(1); 189-96. ©2017 AACRSee related commentary by Cheung and Hsu, p. 3.

Published
2018

9. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Author

Ozkaynak, M Fevzi, Gilman, Andrew L, London, Wendy B, Naranjo, Arlene, Diccianni, Mitchell B, Tenney, Sheena C, Smith, Malcolm, Messer, Karen S, Seeger, Robert, Reynolds, C Patrick, Smith, L Mary, Shulkin, Barry L, Parisi, Marguerite, Maris, John M, Park, Julie R, Sondel, Paul M, and Yu, Alice L

Subjects
anti-GD2 chimeric antibody, cytokine biomarkers, cytokines, immunotherapy, neuroblastoma, safety, Immunology, Medical Microbiology
Abstract

[This corrects the article DOI: 10.3389/fimmu.2018.01355.].

Published
2018

10. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Author

Ozkaynak, M Fevzi, Gilman, Andrew L, London, Wendy B, Naranjo, Arlene, Diccianni, Mitchell B, Tenney, Sheena C, Smith, Malcolm, Messer, Karen S, Seeger, Robert, Reynolds, C Patrick, Smith, L Mary, Shulkin, Barry L, Parisi, Marguerite, Maris, John M, Park, Julie R, Sondel, Paul M, and Yu, Alice L

Subjects
anti-GD2 chimeric antibody, cytokine biomarkers, cytokines, immunotherapy, neuroblastoma, safety, Neurosciences, Pediatric Research Initiative, Pediatric Cancer, Neuroblastoma, Clinical Trials and Supportive Activities, Clinical Research, Pediatric, Rare Diseases, Orphan Drug, Vaccine Related, Immunization, Cancer, Patient Safety, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Immunology, Medical Microbiology
Abstract

PurposeA phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data to support FDA registration of ch14.18.Experimental designNewly diagnosed high-risk NB patients who achieved at least a partial response to induction therapy and received myeloablative consolidation with stem cell rescue were enrolled to receive six courses of isotretinoin with five concomitant cycles of ch14.18 combined with GM-CSF or IL2. Ch14.18 infusion time was 10-20 h per dose. Blood was collected for cytokine analysis and its association with toxicities and outcome.ResultsOf 105 patients enrolled, five patients developed protocol-defined unacceptable toxicities. The most common grade ≥ 3 non-hematologic toxicities of immunotherapy for cycles 1-5, respectively, were neuropathic pain (41, 28, 22, 31, 24%), hypotension (10, 17, 4, 14, 8%), allergic reactions (ARs) (3, 10, 5, 7, 2%), capillary leak syndrome (1, 4, 0, 2, 0%), and fever (21, 59, 6, 32, 5%). The 3-year event-free survival and overall survival were 67.6 ± 4.8% and 79.1 ± 4.2%, respectively. AR during course 1 was associated with elevated serum levels of IL-1Ra and IFNγ, while severe hypotension during this course was associated with low IL5 and nitrate. Higher pretreatment CXCL9 level was associated with poorer event-free survival (EFS).ConclusionThis study has confirmed the significant, but manageable treatment-related toxicities of this immunotherapy and identified possible cytokine biomarkers associated with select toxicities and outcome. EFS and OS appear similar to that previously reported on ANBL0032.

Published
2018

11. SUPPLEMENTAL MATERIALS from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Author

Erbe, Amy K., primary, Wang, Wei, primary, Carmichael, Lakeesha, primary, Kim, KyungMann, primary, Mendonça, Eneida A., primary, Song, Yiqiang, primary, Hess, Dustin, primary, Reville, Patrick K., primary, London, Wendy B., primary, Naranjo, Arlene, primary, Hank, Jacquelyn A., primary, Diccianni, Mitchell B., primary, Reisfeld, Ralph A., primary, Gillies, Stephen D., primary, Matthay, Katherine K., primary, Cohn, Susan L., primary, Hogarty, Michael D., primary, Maris, John M., primary, Park, Julie R., primary, Ozkaynak, M. Fevzi, primary, Gilman, Andrew L., primary, Yu, Alice L., primary, and Sondel, Paul M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Author

Yu, Alice L., primary, Gilman, Andrew L., primary, Ozkaynak, M. Fevzi, primary, Naranjo, Arlene, primary, Diccianni, Mitchell B., primary, Gan, Jacek, primary, Hank, Jacquelyn A., primary, Batova, Ayse, primary, London, Wendy B., primary, Tenney, Sheena C., primary, Smith, Malcolm, primary, Shulkin, Barry L., primary, Parisi, Marguerite, primary, Matthay, Katherine K., primary, Cohn, Susan L., primary, Maris, John M., primary, Bagatell, Rochelle, primary, Park, Julie R., primary, and Sondel, Paul M., primary

Published
2023
Full Text
View/download PDF

13. Table S3 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Author

Erbe, Amy K., primary, Wang, Wei, primary, Carmichael, Lakeesha, primary, Kim, KyungMann, primary, Mendonça, Eneida A., primary, Song, Yiqiang, primary, Hess, Dustin, primary, Reville, Patrick K., primary, London, Wendy B., primary, Naranjo, Arlene, primary, Hank, Jacquelyn A., primary, Diccianni, Mitchell B., primary, Reisfeld, Ralph A., primary, Gillies, Stephen D., primary, Matthay, Katherine K., primary, Cohn, Susan L., primary, Hogarty, Michael D., primary, Maris, John M., primary, Park, Julie R., primary, Ozkaynak, M. Fevzi, primary, Gilman, Andrew L., primary, Yu, Alice L., primary, and Sondel, Paul M., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Information from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Author

Yu, Alice L., primary, Gilman, Andrew L., primary, Ozkaynak, M. Fevzi, primary, Naranjo, Arlene, primary, Diccianni, Mitchell B., primary, Gan, Jacek, primary, Hank, Jacquelyn A., primary, Batova, Ayse, primary, London, Wendy B., primary, Tenney, Sheena C., primary, Smith, Malcolm, primary, Shulkin, Barry L., primary, Parisi, Marguerite, primary, Matthay, Katherine K., primary, Cohn, Susan L., primary, Maris, John M., primary, Bagatell, Rochelle, primary, Park, Julie R., primary, and Sondel, Paul M., primary

Published
2023
Full Text
View/download PDF

15. A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY

Author

Quigg, T., primary, Flower, A., additional, Teachey, D., additional, Lim, M., additional, Chu, Y., additional, Harrison, L., additional, Morris, E., additional, Gardenswartz, A., additional, Hochberg, J., additional, Ozkaynak, M., additional, Rosenblum, J., additional, Milner, J., additional, Pehlivan, K., additional, Levendoglu-Tugal, O., additional, Fabricatore, S., additional, Wolownik, K., additional, Ayello, J., additional, Rigot, O., additional, Klejmont, L., additional, Campbell, M., additional, Gonzalez, I., additional, Otero, N., additional, Budhram, A., additional, Mintzer, E., additional, Mahanti, H., additional, Dufresne, J., additional, Liu, D., additional, Ahmed, T., additional, Steinberg, A., additional, Sweeney, R., additional, McHale, P., additional, Islam, H., additional, Gerard, P., additional, Moorthy, C., additional, Voss, S., additional, Miles, R., additional, Audino, A., additional, Mo, X., additional, Stanek, J., additional, Olshen, A., additional, Hermiston, M., additional, Seif, A., additional, and Cairo, M., additional

Published
2022
Full Text
View/download PDF

16. 121 - A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY

Author

Quigg, T., Flower, A., Teachey, D., Lim, M., Chu, Y., Harrison, L., Morris, E., Gardenswartz, A., Hochberg, J., Ozkaynak, M., Rosenblum, J., Milner, J., Pehlivan, K., Levendoglu-Tugal, O., Fabricatore, S., Wolownik, K., Ayello, J., Rigot, O., Klejmont, L., Campbell, M., Gonzalez, I., Otero, N., Budhram, A., Mintzer, E., Mahanti, H., Dufresne, J., Liu, D., Ahmed, T., Steinberg, A., Sweeney, R., McHale, P., Islam, H., Gerard, P., Moorthy, C., Voss, S., Miles, R., Audino, A., Mo, X., Stanek, J., Olshen, A., Hermiston, M., Seif, A., and Cairo, M.

Published
2022
Full Text
View/download PDF

17. Expression of neuroblastoma‐related genes in bone marrow at end of high‐risk neuroblastoma therapy

Author

Asgharzadeh, Shahab, primary, Marachelian, Araz, additional, Villablanca, Judith G., additional, Liu, Wei Yao, additional, Kennedy, Rebekah, additional, Sposto, Richard, additional, Naranjo, Arlene, additional, Tenney, Sheena, additional, Yu, Alice L., additional, Ozkaynak, M. Fevzi, additional, Sondel, Paul M., additional, Park, Julie R., additional, and Seeger, Robert C., additional

Published
2022
Full Text
View/download PDF

18. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Author

Yu, Alice L, Gilman, Andrew L, Ozkaynak, M Fevzi, Naranjo, Arlene, Diccianni, Mitchell B, Gan, Jacek, Hank, Jacquelyn A, Batova, Ayse, London, Wendy B, Tenney, Sheena C, Smith, Malcolm, Shulkin, Barry L, Parisi, Marguerite, Matthay, Katherine K, Cohn, Susan L, Maris, John M, Bagatell, Rochelle, Park, Julie R, and Sondel, Paul M

Subjects
Male, Adolescent, Pediatric Cancer, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Antibodies, Vaccine Related, Neuroblastoma, Rare Diseases, Clinical Research, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, Humans, Oncology & Carcinogenesis, Isotretinoin, Child, Preschool, Cancer, Pediatric, Prevention, Neurosciences, Infant, Recombinant Proteins, Progression-Free Survival, Interleukin-2, Immunization, Follow-Up Studies
Abstract

PurposePreviously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolidation therapy. These results served as the basis for FDA approval of dinutuximab. We now present long-term follow-up results and evaluation of predictive biomarkers.Patients and methodsPatients recieved six cycles of isotretinoin with or without five cycles of immunotherapy which consists of dinutuximab with GM-CSF alternating with IL2. Accrual was discontinued early due to meeting the protocol-defined stopping rule for efficacy, as assessed by 2-year event-free survival (EFS). Plasma levels of dinutuximab, soluble IL2 receptor (sIL2R), and human anti-chimeric antibody (HACA) were assessed by ELISA. Fcγ receptor 2A and 3A genotypes were determined by PCR and direct sequencing.ResultsFor 226 eligible randomized patients, 5-year EFS was 56.6 ± 4.7% for patients randomized to immunotherapy (n = 114) versus 46.1 ± 5.1% for those randomized to isotretinoin only (n = 112; P = 0.042). Five-year overall survival (OS) was 73.2 ± 4.2% versus 56.6 ± 5.1% for immunotherapy and isotretinoin only patients, respectively (P = 0.045). Thirteen of 122 patients receiving dinutuximab developed HACA. Plasma levels of dinutuximab, HACA, and sIL2R did not correlate with EFS/OS, or clinically significant toxicity. Fcγ receptor 2A and 3A genotypes did not correlate with EFS/OS.ConclusionsImmunotherapy with dinutuximab improved outcome for patients with high-risk neuroblastoma. Early stoppage for efficacy resulted in a smaller sample size than originally planned, yet clinically significant long-term differences in survival were observed.

Published
2021

19. Anti GD2-antibody with GM-CSF, interleukin-2, and isotrectinoin for neuroblastoma

Author

Yu, Alice L., Gilman, Andrew L., Ozkaynak, M. Ferzi, London, Wendy B., Kreissman, Susan G., Chen, Helen X., Smith, Malcolm, Anderson, Barry, Villablanca. Judith G., Matthay, Katherine K., Hiro Shmiada, Grupp, Stephan A., Seeger, Robert, Reynolds, C. Patrick, Buxton, Allan, Reisfield, Ralph A., Gillies, Steven D., Cohn, Susan L., Maris, John M., and Sondel, Paul M.

Subjects
Drug therapy, Combination -- Patient outcomes, Interleukin-2 -- Usage, Interleukin-2 -- Health aspects, Isotretinoin -- Usage, Isotretinoin -- Health aspects, Monoclonal antibodies -- Usage, Monoclonal antibodies -- Health aspects, Neuroblastoma -- Drug therapy, Neuroblastoma -- Risk factors
Abstract

A study was conducted to evaluate whether adding ch14.18, a monoclonal anti GD2-antibody with GM-CSF and interleukin-2, and isotrectinoin would have positive outcomes in the case of patients with neuroblastoma. Results indicated that the combination os such therapies resulted in better outcomes in the case of such patients.

Published
2010

28. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Author

Ozkaynak, M. Fevzi, primary, Gilman, Andrew L., additional, London, Wendy B., additional, Naranjo, Arlene, additional, Diccianni, Mitchell B., additional, Tenney, Sheena C., additional, Smith, Malcolm, additional, Messer, Karen S., additional, Seeger, Robert, additional, Reynolds, C. Patrick, additional, Smith, L. Mary, additional, Shulkin, Barry L., additional, Parisi, Marguerite, additional, Maris, John M., additional, Park, Julie R., additional, Sondel, Paul M., additional, and Yu, Alice L., additional

Published
2018
Full Text
View/download PDF

29. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Author

Ozkaynak, M. Fevzi, primary, Gilman, Andrew L., additional, London, Wendy B., additional, Naranjo, Arlene, additional, Diccianni, Mitchell B., additional, Tenney, Sheena C., additional, Smith, Malcolm, additional, Messer, Karen S., additional, Seeger, Robert, additional, Reynolds, C. Patrick, additional, Smith, L. Mary, additional, Shulkin, Barry L., additional, Parisi, Marguerite, additional, Maris, John M., additional, Park, Julie R., additional, Sondel, Paul M., additional, and Yu, Alice L., additional

Published
2018
Full Text
View/download PDF

30. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia

Author

Hochberg, Jessica, primary, Zahler, Stacey, additional, Geyer, Mark B., additional, Chen, Nan, additional, Krajewski, Jennifer, additional, Harrison, Lauren, additional, Militano, Olga, additional, Ozkaynak, M. Fevzi, additional, Cheerva, Alexandra C., additional, Talano, Julie, additional, Moore, Theodore B., additional, Gillio, Alfred P., additional, Walters, Mark C., additional, Baxter-Lowe, Lee Ann, additional, Hamby, Carl, additional, and Cairo, Mitchell S., additional

Published
2018
Full Text
View/download PDF

32. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

Author

Erbe, Amy K., primary, Wang, Wei, additional, Reville, Patrick K., additional, Carmichael, Lakeesha, additional, Kim, KyungMann, additional, Mendonca, Eneida A., additional, Song, Yiqiang, additional, Hank, Jacquelyn A., additional, London, Wendy B., additional, Naranjo, Arlene, additional, Hong, Fangxin, additional, Hogarty, Michael D., additional, Maris, John M., additional, Park, Julie R., additional, Ozkaynak, M. F., additional, Miller, Jeffrey S., additional, Gilman, Andrew L., additional, Kahl, Brad, additional, Yu, Alice L., additional, and Sondel, Paul M., additional

Published
2017
Full Text
View/download PDF

33. Perioperative Management in Children with Sickle Cell Disease Undergoing Laparoscopic Surgery

Author

Sandoval, Claudio, Stringel, Gustavo, Ozkaynak, M. Fevzi, Tugal, Oya, and Jayabose, Somasundaram

Subjects
Male, Anemia, Sickle Cell, Laparoscopic surgery, Adolescence, Postoperative Complications, Cholecystectomy, Laparoscopic, Cholelithiasis, Preoperative Care, Splenomegaly, Scientific Papers, Sickle cell anemia, Splenectomy, Humans, Blood Transfusion, Female, Laparoscopy, Child, Retrospective Studies
Abstract

Objective: The aim of this study was to evaluate our experience with laparoscopic surgery in children with sickle cell disease. Methods: A retrospective chart review was performed to analyze the indication for surgery, perioperative management, surgical technique, complications, duration of hospitalization, and outcome. One pediatric surgeon performed all procedures. Results: Thirteen children underwent laparoscopic surgery for the following indications: symptomatic cholelithiasis/cholecystitis in 9; recurrent splenic sequestration in 3; and hypersplenism/symptomatic cholelithiasis in 1. The 7 boys and 6 girls had a median age of 7.8 years. Patients undergoing splenectomy only were younger than those undergoing cholecystectomy (median age, 3.6 years versus 11.5 years, respectively). Four children underwent endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy because of common bile duct dilatation and stones. Twelve patients received packed red blood cell transfusions prior to surgery. The median operative time was 150 minutes, and the median hospitalization was 3 days. Four patients suffered postoperative complications (2 with acute chest syndrome, 1 with recurrent abdominal pain, and 1 with priapism). The patient with abdominal pain was found to have a retained stone in the common bile duct, which was retrieved via endoscopic retrograde cholangiopancreatography and sphincterotomy. All complications resolved with medical management. Conclusions: Laparoscopic surgery is safe in children with sickle cell disease. Meticulous attention to perioperative management, transfusion guidelines, and pulmonary care may decrease the incidence of acute chest syndrome.

Published
2002

37. Lastdatenermittlung für die rechnerische Lebensdauerabschätzung eines neuen Bustyps

Author

Bäcker, M., Möller, R., Kienert, M., Bayram, B., Ozkaynak, M., and Publica

Subjects
Lebensdauerabschätzung, Bus, Lastdatenermittlung
Abstract

In diesem Beitrag wird der Prozess zur virtuellen Ermittlung der Lastdaten für eine rechnerische Lebensdauerabschätzung eines neu entwickelten Bustyps beschrieben. Dieser Prozess war Teil eines gemeinsamen Projekts von Temsa und LMS, das zum Ziel hatte den gesamten CAE-basierten Betriebsfestigkeitsprozess, beginnend mit der Ableitung der Kundenbeanspruchungsprofile bis hin zu rechnerischen Lebensdauerabschätzung der Busstruktur, bei Temsa zu etablieren. Die besondere Herausforderung in diesem Projekt war es, den Prozess der virtuellen Lastdatenermittlung so zu gestalten, dass ein guter Kompromiss zwischen Aufwand, Genauigkeit und Nachhaltigkeit erzielt wurde. Mit der verwendeten "Hybrid Road"-Methode erfolgt eine Rückrechnung des effektiven Straßenprofils, basierend auf Messgrößen (Messradkräfte) die mit einem entsprechenden Prototyp des Entwicklungsfahrzeugs auf der Teststrecke aufgezeichnet werden. Das zurückgerechnete Straßenprofil kann dann zur virtuellen Lastdatenbestimmung für Fahrzeugvarianten verwendet werden, ohne die zeit- und kostenaufwändigen Messungen zu wiederholen.

Published
2009

38. Low Day 100 Transplant-Related Mortality and Relapse Rate Following Clofarabine in Combination with Cytarabine, Total Body Irradiation and Allogenic Stem Cell Transplantaiton in Children, Adolescents and Young Adults with Poor-Risk Acute Leukemia

Author

Chen, Nan, primary, Radhakrishnan, Kavita, additional, Krajewski, Jennifer, additional, Ricci, Angela, additional, Geyer, Mark, additional, Harrison, Lauren, additional, Ozkaynak, M Fevzi, additional, Cheerva, Alexandra, additional, Talano, Julie-An, additional, Moore, Theodore B., additional, Gillio, Alfred P., additional, Walters, Mark, additional, Baxter-Lowe, Lee Ann, additional, and Cairo, Mitchell S., additional

Published
2014
Full Text
View/download PDF

40. Low Day 100 Transplant-Related Mortality (TRM) and Relapse Rate Following Clofarabine in Combination With Cytarabine, Total Body Irradiation and Allogeneic Stem Cell Transplantation in Children, Adolescents and Young Adults with Poor-Risk Acute Leukemia

Author

Krajewski, Jennifer, primary, Radhakrishnan, Kavita, additional, Chen, Nan, additional, Ricci, Angela, additional, Geyer, Mark, additional, Harrison, Lauren, additional, Ozkaynak, M. Fevzi, additional, Satwani, Prakash, additional, Cheerva, Alexandra, additional, Talano, Julie-An, additional, Moore, Theodore B., additional, Gillio, Alfred P., additional, Baxter-Lowe, Lee Ann, additional, and Cairo, Mitchell S., additional

Published
2013
Full Text
View/download PDF

43. Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

Author

Gilman, Andrew L., primary, Ozkaynak, M. Fevzi, additional, Matthay, Katherine K., additional, Krailo, Mark, additional, Yu, Alice L., additional, Gan, Jacek, additional, Sternberg, Adam, additional, Hank, Jacquelyn A., additional, Seeger, Robert, additional, Reaman, Gregory H., additional, and Sondel, Paul M., additional

Published
2009
Full Text
View/download PDF

44. Untreated head and neck neuroblastoma

Author

Bjornard, Kari, primary, Jayabose, Somasundaram, additional, Ozkaynak, M. Fevzi, additional, Tugal, Oya, additional, Sandoval, Claudio, additional, and McBride, Whitney, additional

Published
2008
Full Text
View/download PDF

45. A Pilot Study of Addition of Amifostine to Melphalan, Carboplatin, Etoposide, and Cyclophosphamide With Autologous Hematopoietic Stem Cell Transplantation in Pediatric Solid Tumors–A Pediatric Blood and Marrow Transplant Consortium Study

Author

Ozkaynak, M. Fevzi, primary, Sahdev, Indira, additional, Gross, Thomas G., additional, Levine, John E., additional, Cheerva, Alexandra C., additional, Richards, Michael K., additional, Rozans, Marta K., additional, Shaw, Peter J., additional, and Kadota, Richard P., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results